Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Phase I, Open-label, Multicentre, Dose Escalation Trial of BI 3819026 in Combination With Ezabenlimab in Patients With Unresectable Advanced or Metastatic Solid Cancers to Determine the Maximum Tolerated Dose (MTD) and Recommended Dose for Expansion (RDE)

NCT07607678 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07607678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07607678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Phase I, Open-label, Multicentre, Dose Escalation Trial of BI 3819026 in Combination With Ezabenlimab in Patients With Unresectable Advanced or Metastatic Solid Cancers to Determine the Maximum Tolerated Dose (MTD) and Recommended Dose for Expansion (RDE)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Recruiting
Start date
May 1, 2026
Completion date
October 15, 2030
Enrollment
60 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid cancer, metastatic solid cancer